Vein Pick Model 6541
Boston Scientific · Decision date Apr 10, 2026
What did the FDA approve?
FDA records P830060/S092 as a supplement to PMA P830060, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 10, 2026.
FDA approval order statement
approval for minor labeling changes, removal of paper IFU, and minor dimensional changes to sterile pouches
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 10, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P830060/S092
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific
- Product code
- LWS
- Decision code
- APPR
- Decision date
- Apr 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Boston Scientific
- Product code
- LWS
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P830060/S091 · Related supplement
ACC SUP VEIN PICK
P830060/S092 received
Application receipt date recorded by FDA.
P830060/S092 · FDA decision
Real-Time Process
P830060/S093 · Related supplement
Vein Pick (Model 6541)
Timeline entries are records held by MedtechLedger for P830060. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P830060
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ACC SUP VEIN PICKP830060/S091 | Boston Scientific | PMA supplement | Sep 16, 2025 | FDA |
Vein Pick (Model 6541)P830060/S093 | Boston Scientific | PMA supplement | May 15, 2026 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P830060/S092
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


